Response to Letter to Editor

Timothy J Kaufmann¹, Marion Smits², Jerrold Boxerman³, Raymond Huang⁴, Daniel P Barboriak⁵, Michael Weller⁶, Caroline Chung⁷, Christina Tsien⁸, Paul D Brown⁹, Lalitha Shankar¹⁰, Evanthia Galanis¹¹, Elizabeth Gerstner¹², Martin J van den Bent¹³, Terry C Burns¹⁴, Ian F Parney¹⁴, Gavin Dunn¹⁵, Priscilla K Brastianos¹⁶, Nancy U Lin¹⁷, Patrick Y Wen¹⁸, Benjamin M Ellingson^{19

20}

Affiliations

¹ Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
³ Department of Diagnostic Imaging, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
⁴ Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁵ Department of Radiology, Duke University School of Medicine, Durham, North Carolina, USA.
⁶ Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
⁷ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁸ Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
⁹ Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
¹⁰ Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
¹¹ Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
¹² Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹³ Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
¹⁴ Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ Department of Neurological Surgery, Washington University, St Louis, Missouri, USA.
¹⁶ Departments of Medicine and Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
¹⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹⁸ Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
¹⁹ UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
²⁰ Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

PMID: 32823280
PMCID: PMC7690353
DOI: 10.1093/neuonc/noaa202

Comment

Response to Letter to Editor

Timothy J Kaufmann et al. Neuro Oncol. 2020.

. 2020 Nov 26;22(11):1706-1707.

doi: 10.1093/neuonc/noaa202.

Authors

Affiliations

¹ Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
³ Department of Diagnostic Imaging, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
⁴ Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁵ Department of Radiology, Duke University School of Medicine, Durham, North Carolina, USA.
⁶ Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
⁷ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁸ Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
⁹ Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
¹⁰ Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
¹¹ Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
¹² Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
¹³ Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
¹⁴ Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
¹⁵ Department of Neurological Surgery, Washington University, St Louis, Missouri, USA.
¹⁶ Departments of Medicine and Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
¹⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
¹⁸ Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
¹⁹ UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
²⁰ Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

PMID: 32823280
PMCID: PMC7690353
DOI: 10.1093/neuonc/noaa202

No abstract available

PubMed Disclaimer

Comment on

Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.
Kaufmann TJ, Smits M, Boxerman J, Huang R, Barboriak DP, Weller M, Chung C, Tsien C, Brown PD, Shankar L, Galanis E, Gerstner E, van den Bent MJ, Burns TC, Parney IF, Dunn G, Brastianos PK, Lin NU, Wen PY, Ellingson BM. Kaufmann TJ, et al. Neuro Oncol. 2020 Jun 9;22(6):757-772. doi: 10.1093/neuonc/noaa030. Neuro Oncol. 2020. PMID: 32048719 Free PMC article.
Letter regarding "Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases".
Arana E, Arribas LA. Arana E, et al. Neuro Oncol. 2020 Nov 26;22(11):1705. doi: 10.1093/neuonc/noaa176. Neuro Oncol. 2020. PMID: 32735663 Free PMC article. No abstract available.

References

1. Kaufmann TJ, Smits M, Boxerman J, et al. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol. 2020;22(6):757–772. - PMC - PubMed
1. Wardlaw JM, Brindle W, Casado AM, et al. ; SINAPSE Collaborative Group A systematic review of the utility of 1.5 versus 3 tesla magnetic resonance brain imaging in clinical practice and research. Eur Radiol. 2012;22(11):2295–2303. - PubMed
1. Nöbauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla. Invest Radiol. 2002;37(3):114–119. - PubMed
1. Ba-Ssalamah A, Nöbauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol. 2003;38(7):415–422. - PubMed
1. Lin NU, Lee EQ, Aoyama H, et al. ; Response Assessment in Neuro-Oncology (RANO) group Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270–e278. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

P50 CA211015/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to Letter to Editor

Affiliations

Response to Letter to Editor

Authors

Affiliations

Comment on

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical